NCT01492582View on ClinicalTrials.gov

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

PHASE2CompletedINTERVENTIONAL
Enrollment

1,499

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 8, 2019

Study Completion Date

July 20, 2020

Conditions
Cancer SurvivorPrevention of Human Papillomavirus Infection
Interventions
BIOLOGICAL

quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)

Given IM

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

survey administration

Ancillary studies

OTHER

medical chart review

Ancillary studies

Trial Locations (5)

30308

Emory University School Of Medicine, Atlanta

35233

University of Alabama at Birmingham, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

48109

University of Michigan, Ann Arbor

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT01492582 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors | Biotech Hunter | Biotech Hunter